Qualigen Therapeutics (NASDAQ:QLGN) (NASDAQ: QLGN) is a clinical-stage biotechnology company engaged in the development of targeted immunotherapeutics and high-fidelity diagnostic assays. Headquartered in San Diego, California, Qualigen leverages proprietary platforms to address critical unmet needs in oncology through innovative biologic therapies and rapid immunodiagnostic solutions. Since its founding in 1992 and its rebranding in 2019, the company has built a pipeline of tri-specific antibody constructs and robust assay technologies.
The company’s Tri-Functional Conjugate (TriTAC) platform is designed to engage patients’ endogenous immune effectors, such as T cells and natural killer cells, in the selective elimination of malignant cells. Qualigen’s lead TriTAC candidates are being evaluated in clinical trials for hematologic malignancies and solid tumors, including cutaneous T-cell lymphoma and acute myeloid leukemia. By integrating tumor-targeted antibody fragments with immune-activating cytokine payloads, the platform aims to increase potency, reduce off-target toxicity and overcome resistance mechanisms.
Complementing its therapeutic programs, Qualigen maintains a diagnostics business built around its high-sensitivity immunoassay platform. These assays are used in food safety, environmental monitoring and clinical settings to detect pathogens and biomarkers with rapid turnaround times. The company’s benchtop systems and kit-based formats have been deployed across North America, Europe and Asia, supporting applications in quality control and disease screening.
Qualigen is led by President and Chief Executive Officer Dr. Steven W. King, a recognized leader in biotechnology innovation, and Chief Financial Officer John T. Chriss. The company’s board and management team bring decades of experience in drug development, regulatory affairs and commercial operations. As Qualigen advances its dual diagnostic-and-therapeutic strategy, it continues to pursue collaborations and partnerships to accelerate the translation of its pipelines into clinical and commercial success.
